PURPOSE: The purpose was to examine the effect of pretreatment weight status on loco-regional progression for patients with squamous cell carcinoma of the head and neck (SCCHN) after receiving definitive concurrent chemoradiation therapy (CCRT). METHODS: In an expanded cohort of 140 patients, we retrospectively reviewed weight status and loco-regional progression of SCCHN patients treated with CCRT between 2004 and 2010. RESULTS: Pretreatment ideal body weight percentage (IBW%) was statistically significantly different for patients with disease progression than for those without progression (p = 0.02) but was not an independent predictor of progression. Median pretreatment IBW% was 118 (72-193) for the progression-free group and was 101.5 (73-163) for the group with progression. Both groups suffered clinically severe weight loss of approximately 9 % from baseline to end treatment. CONCLUSIONS: Pretreatment weight status, a very crude indicator of nutrition status, may have prognostic value in patients with SCCHN undergoing definitive CCRT. Inadequate nutritional status in these patients has been associated with poor clinical outcomes and decreased quality of life. Based on this report and others, the best next steps include routine validated malnutrition screening and the testing of evidence-based nutrition care protocols with the goals of minimizing weight loss and improvement of quality of life.
PURPOSE: The purpose was to examine the effect of pretreatment weight status on loco-regional progression for patients with squamous cell carcinoma of the head and neck (SCCHN) after receiving definitive concurrent chemoradiation therapy (CCRT). METHODS: In an expanded cohort of 140 patients, we retrospectively reviewed weight status and loco-regional progression of SCCHN patients treated with CCRT between 2004 and 2010. RESULTS: Pretreatment ideal body weight percentage (IBW%) was statistically significantly different for patients with disease progression than for those without progression (p = 0.02) but was not an independent predictor of progression. Median pretreatment IBW% was 118 (72-193) for the progression-free group and was 101.5 (73-163) for the group with progression. Both groups suffered clinically severe weight loss of approximately 9 % from baseline to end treatment. CONCLUSIONS: Pretreatment weight status, a very crude indicator of nutrition status, may have prognostic value in patients with SCCHN undergoing definitive CCRT. Inadequate nutritional status in these patients has been associated with poor clinical outcomes and decreased quality of life. Based on this report and others, the best next steps include routine validated malnutrition screening and the testing of evidence-based nutrition care protocols with the goals of minimizing weight loss and improvement of quality of life.
Authors: Nicole K Kiss; Meinir Krishnasamy; Jenelle Loeliger; Alba Granados; Gaelle Dutu; June Corry Journal: Support Care Cancer Date: 2011-11-16 Impact factor: 3.603
Authors: P García-Peris; L Parón; C Velasco; C de la Cuerda; M Camblor; I Bretón; H Herencia; J Verdaguer; C Navarro; P Clave Journal: Clin Nutr Date: 2007-10-22 Impact factor: 7.324
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Theodore R McRackan; John M Watkins; Amy E Herrin; Elizabeth M Garrett-Mayer; Anand K Sharma; Terry A Day; M Boyd Gillespie Journal: Laryngoscope Date: 2008-07 Impact factor: 3.325
Authors: Elisabeth Isenring; Giordana Cross; Lynne Daniels; Elizabeth Kellett; Bogda Koczwara Journal: Support Care Cancer Date: 2006-04-19 Impact factor: 3.359
Authors: Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Elizabeth A Repasky; Anurag K Singh Journal: Oral Oncol Date: 2020-06-16 Impact factor: 5.337
Authors: Xiao-Su Hu; Clayton A Fisher; Stephanie M Munz; Rebecca L Toback; Thiago D Nascimento; Emily L Bellile; Laura Rozek; Avraham Eisbruch; Francis P Worden; Theodora E Danciu; Alexandre F DaSilva Journal: Front Hum Neurosci Date: 2016-09-27 Impact factor: 3.169
Authors: Camilla K Lonkvist; Simon Lønbro; Anders Vinther; Bo Zerahn; Eva Rosenbom; Hanne Primdahl; Pernille Hojman; Julie Gehl Journal: BMC Cancer Date: 2017-06-03 Impact factor: 4.430
Authors: Camilla K Lonkvist; Anders Vinther; Bo Zerahn; Eva Rosenbom; Atul S Deshmukh; Pernille Hojman; Julie Gehl Journal: Laryngoscope Investig Otolaryngol Date: 2017-07-19
Authors: Ron R Allison; Aaron A Ambrad; Youssef Arshoun; Richard J Carmel; Doug F Ciuba; Elizabeth Feldman; Steven E Finkelstein; Ranjini Gandhavadi; Dwight E Heron; Steven C Lane; John M Longo; Charles Meakin; Dimitrios Papadopoulos; David E Pruitt; Lynn M Steinbrenner; Michael A Taylor; William M Wisbeck; Grace E Yuh; David P Nowotnik; Stephen T Sonis Journal: Cancer Date: 2014-05-01 Impact factor: 6.860
Authors: Hye Ri Han; Gregory M Hermann; Sung Jun Ma; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni A Kuriakose; Michael R Markiewicz; Jon M Chan; Mary E Platek; Andrew D Ray; Fangyi Gu; Wesley L Hicks; Anurag K Singh Journal: Ann Transl Med Date: 2021-05